Toll Free: 1-888-928-9744

Cough - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 96 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cough - Pipeline Review, H2 2016


Global Markets Direct's, 'Cough - Pipeline Review, H2 2016', provides an overview of the Cough pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Cough, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cough and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


- The report provides a snapshot of the global therapeutic landscape of Cough
- The report reviews pipeline therapeutics for Cough by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Cough therapeutics and enlists all their major and minor projects
- The report assesses Cough therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Cough

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Cough
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cough pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Cough Overview 9 Therapeutics Development 10 Pipeline Products for Cough - Overview 10 Pipeline Products for Cough - Comparative Analysis 11 Cough - Therapeutics under Development by Companies 12 Cough - Therapeutics under Investigation by Universities/Institutes 14 Cough - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Cough - Products under Development by Companies 19 Cough - Products under Investigation by Universities/Institutes 20 Cough - Companies Involved in Therapeutics Development 21 Afferent Pharmaceuticals, Inc. 21 Alitair Pharmaceuticals, Inc. 22 Alveonix AG 23 AstraZeneca Plc 24 AusBio Ltd 25 Charleston Laboratories, Inc. 26 Conrig Pharma ApS 27 Daewoong Pharmaceutical Co., Ltd. 28 GlaxoSmithKline Plc 29 Glenmark Pharmaceuticals Ltd. 30 GW Pharmaceuticals Plc 31 Hyundai Pharmaceutical Co., Ltd. 32 Johnson & Johnson 33 NeRRe Therapeutics Ltd 34 Orbis Biosciences Inc 35 Patara Pharma, Inc. 36 Pila Pharma AB 37 Vernalis Plc 38 Cough - Therapeutics Assessment 39 Assessment by Monotherapy Products 39 Assessment by Combination Products 40 Assessment by Target 41 Assessment by Mechanism of Action 43 Assessment by Route of Administration 45 Assessment by Molecule Type 47 Drug Profiles 48 Ax-8 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 benzonatate - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 CCP-05 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 CCP-06 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 CCP-07 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 CCP-08 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 CLAT-313 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 codeine + guaifenesin - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 cromolyn sodium - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 DWJ-1340 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 GRC-17536 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 GSK-2339345 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 guaifenesin + hydrocodone - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 guaifenesin ER - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 JNJ-39729209 - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 lesogaberan - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 levodropropizine CR - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 MD-990 - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 MK-7264 - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 NEO-5937 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 orvepitant maleate - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 S-1226 - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 Small Molecule to Antagonize TRPA-1 for Pain And Respiratory Disorders - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 Small Molecules to Agonize CB1 and CB2 for Chronic Cough and Inflammatory Skin Diseases - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 ST-015 - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 XEND-0501 - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 Cough - Dormant Projects 81 Cough - Discontinued Products 84 Cough - Product Development Milestones 85 Featured News & Press Releases 85 Jul 08, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Comparative Bioavailability Study 85 May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference 85 May 03, 2016: Patara Pharma Appoints Biotechnology Industry Leader John Schmid to Board of Directors 87 Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference 88 Apr 14, 2016: Vernalis Announces Successful Completion of CCP-07 Pivotal Multiple-Dose Comparative Bioavailability Study 88 Apr 13, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Single-Dose Comparative Bioavailability Study 88 Dec 21, 2015: Vernalis Announces Successful Completion of CCP-07 Pivotal Single-Dose Comparative Bioavailability Study 89 Oct 12, 2015: Vernalis announces start of CCP-08 12 month stability testing 89 Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial 90 Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine 91 Jun 11, 2015: Vernalis announces CCP-07 starts 12 month stability testing 91 Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet 91 Sep 09, 2014: Charleston Laboratories Announces Key Clinical Updates for Novel Drug 93 Jul 22, 2014: Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 93 Apr 29, 2014: Second Product in Vernalis' Cough Cold Pipeline Achieves Proof-of-Concept 93 Appendix 95 Methodology 95 Coverage 95 Secondary Research 95 Primary Research 95 Expert Panel Validation 95 Contact Us 95 Disclaimer 96
List of Tables
Number of Products under Development for Cough, H2 2016 10 Number of Products under Development for Cough - Comparative Analysis, H2 2016 11 Number of Products under Development by Companies, H2 2016 13 Number of Products under Investigation by Universities/Institutes, H2 2016 14 Comparative Analysis by Late Stage Development, H2 2016 15 Comparative Analysis by Clinical Stage Development, H2 2016 16 Comparative Analysis by Early Stage Development, H2 2016 17 Comparative Analysis by Unknown Stage Development, H2 2016 18 Products under Development by Companies, H2 2016 19 Products under Investigation by Universities/Institutes, H2 2016 20 Cough - Pipeline by Afferent Pharmaceuticals, Inc., H2 2016 21 Cough - Pipeline by Alitair Pharmaceuticals, Inc., H2 2016 22 Cough - Pipeline by Alveonix AG, H2 2016 23 Cough - Pipeline by AstraZeneca Plc, H2 2016 24 Cough - Pipeline by AusBio Ltd, H2 2016 25 Cough - Pipeline by Charleston Laboratories, Inc., H2 2016 26 Cough - Pipeline by Conrig Pharma ApS, H2 2016 27 Cough - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 28 Cough - Pipeline by GlaxoSmithKline Plc, H2 2016 29 Cough - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 30 Cough - Pipeline by GW Pharmaceuticals Plc, H2 2016 31 Cough - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 32 Cough - Pipeline by Johnson & Johnson, H2 2016 33 Cough - Pipeline by NeRRe Therapeutics Ltd, H2 2016 34 Cough - Pipeline by Orbis Biosciences Inc, H2 2016 35 Cough - Pipeline by Patara Pharma, Inc., H2 2016 36 Cough - Pipeline by Pila Pharma AB, H2 2016 37 Cough - Pipeline by Vernalis Plc, H2 2016 38 Assessment by Monotherapy Products, H2 2016 39 Assessment by Combination Products, H2 2016 40 Number of Products by Stage and Target, H2 2016 42 Number of Products by Stage and Mechanism of Action, H2 2016 44 Number of Products by Stage and Route of Administration, H2 2016 46 Number of Products by Stage and Molecule Type, H2 2016 47 Cough - Dormant Projects, H2 2016 81 Cough - Dormant Projects (Contd..1), H2 2016 82 Cough - Dormant Projects (Contd..2), H2 2016 83 Cough - Discontinued Products, H2 2016 84

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.